What is claimed is:

1. A compound of Formula (I) or (II)


(I)


(II)

wherein

n is 1, 2, or 3;

R^{53} is

(i) phenyl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C_1-C_6)alkyl, halo-substituted (C_1-C_6)alkyl, (C_1-C_6)alkoxy, $-NH_2$, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, $-C(O)NH_2$, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, or a 5- to 6-membered heterocycle,

(ii) biphenyl optionally substituted with 1 to 3 substituents selected from (C_1-C_4)alkyl or halo,

(iii) phenyl fused to an additional phenyl, a 5- to 6-membered heteroaryl, a 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused phenyl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy-substituted (C_1-C_4)alkyl, halo-substituted (C_1-C_6)alkyl, cyclopropyl, oxo, $-NH_2$, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, or =N-OH,

(iv) 5- to 6-membered heteroaryl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C_1-C_6)alkyl, halo-substituted (C_1-C_6)alkyl, (C_1-C_6)alkoxy, $-NH_2$, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, $-C(O)NH_2$, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, or a 5- to 6-membered heterocycle,

(v) 5- to 6-membered heteroaryl fused to another 5- to 6-membered heteroaryl, phenyl, 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered

partially or fully saturated heterocycle, where said fused heteroaryl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy-substituted (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, cyclopropyl, oxo, $-NH_2$, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, or =N-OH;

R^{54} is (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, or $-CH_2OH$, or two R^{54} taken together with the carbon atom(s) to which they are attached form a 3- to 6-membered fully or partially saturated carbocyclic ring or two R^{54} attached to adjacent carbons taken together with the carbons to which they are attached form a fused phenyl;

p is 0, 1, 2, or 3;

q is 0, 1 or 2;

A is a 5- to 6-membered heteroaryl containing one or more nitrogen atom(s), where said heteroaryl is optionally substituted with 1 to 3 substituents each independently selected from halo, -OH, -CN, (C_1-C_4)alkyl, halo-substituted(C_1-C_4)alkyl, hydroxy-substituted (C_1-C_4)alkyl, -(CH_2)$_r$O(C_1-C_4)alkyl, -(CH_2)$_r$CH(O(C_1-C_4)alkyl)$_2$, -NH(C_1-C_4)alkyl, -(CH_2)$_s$NH(C_1-C_4)alkyl, -(CH_2)$_r$N((C_1-C_4)alkyl)$_2$, -(CH_2)$_r$NH(C_3-C_6)cycloalkyl), $-NH_2$, -NHC(O)-(C_1-C_4)alkyl, $-C(O)NH_2$, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, or -C(O)-O(C_1-C_4)alkyl, where said (C_1-C_4)alkyl, said -(CH_2)$_r$O(C_1-C_4)alkyl, and said -(CH_2)$_s$NH(C_1-C_4)alkyl are optionally substituted with a 4- to 6-membered partially or fully saturated heterocycle or heteroaryl containing 1 to 3 heteroatoms each independently selected from O, S or N, where said heterocycle and said heteroaryl are optionally substituted with 1 to 3 (C_1-C_4)alkyl groups;

r is 0, 1 or 2;

s is 1 or 2; or a pharmaceutically acceptable salt thereof;

with the proviso that (i) when A is an unsubstituted pyridine and R^{53} is phenyl, R^{53} is not unsubstituted or mono-substituted with halogen, CH_3, NH_2, -NHC(O)CH_3, or CF_3; (ii) A and R^{53} are not both an unsubstituted pyridin-2-yl; and (iii) said compound is not 1-(3,4-dichloro-phenyl)-3-[6-(2-piperidin-1-yl-ethoxy)-pyridin-3-yl]imidazolidine-2-one, 1-(3,5-dichloropyridin-2-yl)-3-phenyltetrahydropyrimidin-2(1H)-one, 1,3-bis(6-chloropyridin-2-yl)tetrahydropyrimidin-2(1H)-one, 1,3-bis(4-methylpyridin-2-

Action: 24.03.2011 19:19:06 - 24.03.2011 19:22:31. This page 11 of 11 011 19:22:31
Received at the EPO on Mar 24, 2011 19:22:31. Page 11 of 11 24/03/2011

yl)imidazolidin-2-one, 1-(5-chloro-1H-benzo[d]imidazol-2-yl)-3-phenylimidazolidin-2-one, or 2-(2-oxo-3-phenylimidazolidin-1-yl)-1H-benzo[d]imidazole-5-carbonitrile.

2. A compound of Claim 1 wherein A is a 6-membered heteroaryl containing 1 to 2 nitrogen atom(s), where said heteroaryl is optionally substituted with (C_1-C_4)alkyl; or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 1 wherein A is a pyridine, where said pyridine is optionally substituted with 1 to 3 substituents each independently selected from halo, -CN, (C_1-C_4)alkyl, halo-substituted(C_1-C_4)alkyl, hydroxy-substituted (C_1-C_4)alkyl, -$(CH_2)_r$O(C_1-C_4)alkyl, -$(CH_2)_r$CH(O(C_1-C_4)alkyl)$_2$, -$(CH_2)_r$NH(C_1-C_4)alkyl, -$(CH_2)_r$N((C_1-C_4)alkyl)$_2$, -$(CH_2)_r$NH(C_3-C_6)cycloalkyl), -NH_2, -NHC(O)-(C_1-C_4)alkyl, -$C(O)NH_2$, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, or -C(O)-O(C_1-C_4)alkyl, where said (C_1-C_4)alkyl, said -$(CH_2)_r$O(C_1-C_4)alkyl, and said -$(CH_2)_r$NH(C_1-C_4)alkyl are optionally substituted with a 5- to 6-membered partially or fully saturated heterocycle or heteroaryl containing 1 to 2 heteroatoms each independently selected from O, S or N, where said heterocycle and said heteroaryl are optionally substituted with 1 to 3 (C_1-C_4)alkyl groups;

r is 1 or 2;

or a pharmaceutically acceptable salt thereof.

4. The compound of Claim 3 wherein said optionally substituted pyridine is an optionally substituted pyridin-3-yl; or a pharmaceutically acceptable salt thereof.

5. The compound of Claim 1 having Formula (Ia) or (Ib)


(Ia)


(Ib)

wherein n, R^{50}, R^{51}, R^{52}, R^{53}, R^{54} and q are as defined in Claim 1; or a pharmaceutically acceptable salt thereof.

6. A compound of Formula (Ia) or (Ib)


(Ia)


(Ib)

wherein:

n is 1, 2, or 3;

R^{53} is

(i) phenyl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, $(C_1$-$C_6)$alkyl, halo-substituted $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $-NH_2$, $-NH(C_1$-$C_4)$alkyl, $-N((C_1$-$C_4)alkyl)_2$, $-NHC(O)$-$(C_1$-$C_4)$alkyl, $-C(O)NH_2$, $-C(O)$-$NH(C_1$-$C_4)$alkyl, $-C(O)$-$N((C_1$-$C_4)alkyl)_2$, or a 5- to 6-membered heterocycle,

(ii) biphenyl optionally substituted with 1 to 3 substituents selected from $(C_1$-$C_4)$alkyl or halo,

(iii) phenyl fused to an additional phenyl, a 5- to 6-membered heteroaryl, a 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused phenyl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy,

hydroxy-substituted (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, cyclopropyl, oxo, -NH_2, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, or =N-OH,

(iv) 5- to 6-membered heteroaryl optionally substituted with 1 to 3 substituents selected from halo, -CN, -OH, (C_1-C_6)alkyl, halo-substituted (C_1-C_6)alkyl, (C_1-C_6)alkoxy, -NH_2, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, -C(O)NH_2, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, or a 5- to 6-membered heterocycle,

(v) 5- to 6-membered heteroaryl fused to another 5- to 6-membered heteroaryl, phenyl, 5- to 6-membered partially or fully saturated cycloalkyl, or a 5- to 6-membered partially or fully saturated heterocycle, where said fused heteroaryl is optionally substituted with 1 to 4 substituents each independently selected from halo, -CN, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy-substituted (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, cyclopropyl, oxo, -NH_2, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, or =N-OH;

R^{54} is (C_1-C_4)alkyl, halo-substituted (C_1-C_4)alkyl, or –CH_2OH, or two R^{54} taken together with the carbon atom(s) to which they are attached form a 3- to 6-membered fully or partially saturated carbocyclic ring;

p is 0, 1, 2, or 3;

q is 0, 1 or 2;

R^{50}, R^{51} and R^{52} are each independently H, halo, -OH, -CN, (C_1-C_4)alkyl, halo-substituted(C_1-C_4)alkyl, hydroxy-substituted (C_1-C_4)alkyl, -(CH_2)$_r$-O(C_1-C_4)alkyl, -(CH_2)$_r$-CH(O(C_1-C_4)alkyl)$_2$, -NH_2, -NH(C_1-C_4)alkyl, -N((C_1-C_4)alkyl)$_2$, -NHC(O)-(C_1-C_4)alkyl, -C(O)NH_2, -C(O)-NH(C_1-C_4)alkyl, -C(O)-N((C_1-C_4)alkyl)$_2$, or -C(O)-O(C_1-C_4)alkyl;

r is 0, 1 or 2;

with the proviso that when R^{50}, R^{51}, and R^{52} are H and R^{53} is phenyl, R^{53} is not unsubstituted or substituted with halogen or CF_3,

or a pharmaceutically acceptable salt thereof.

7. The compound of Claim 6 wherein said compound is a compound of Formula (Ia); or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 7 where q is 0; or a pharmaceutically acceptable salt thereof.

9. The compound of Claim 6 wherein said compound is a compound of Formula (Ib); or a pharmaceutically acceptable salt thereof.

10. The compound of Claim 9 wherein R^{54} is $-CH_3$ or CF_3; or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 9 or 10 wherein n is 1; or a pharmaceutically acceptable salt thereof.

12. The compound of Claim 6, 7, 8, 9, 10 or 11 wherein R^{50} is H or methyl; R^{51} is H, halo, methyl, trifluoromethyl, methoxy, or $-C(O)OCH_3$; and R^{52} is halo, -CN, methyl, ethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropan-2-yl, difluoromethyl, trifluoromethyl, dimethoxymethyl, $-NH_2$, or $-NHC(O)CH_3$; or a pharmaceutically acceptable salt thereof.

13. The compound of Claim 6, 7, 8, 9, 10, 11 or 12 wherein R^{53} is

(i) a phenyl optionally substituted with 1 or 2 substituents each independently selected form fluoro, chloro, cyano, methyl, difluoromethyl, trifluoromethyl, methoxy, or $-C(O)NHCH_3$;

(ii) a biphenyl optionally substituted with fluoro;

(iii) a fused phenyl selected from naphthalen-2-yl, naphthalen-1-yl, 1H-indol-5-yl, 1H-indol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, 1,2,3,4-tetrahydro-quinolin-6-yl, benzo[b]thiophen-5-yl, quinolin-6-yl, quinolin-7-yl, indan-5-yl, 1,2-dihydroquinolin-6-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, benzofuran-5-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, benzo[1,3]dioxol-5-yl, 1,2,3,4-tetrahydro-quinolin-7-yl, quinoxalin-6-yl, benzooxazol-5-yl, benzo[d]isoxazol-5-yl, benzo[d]isoxazol-6-yl, 1H-benzoimidazol-5-yl, 2,3-dihydro-1H-indazol-5-yl, 2,3-dihydro-1H-indazol-6-yl, indolin-5-yl, or 1H-benzotriazol-5-yl, where said fused phenyl is optionally substituted with 1 to

3 substituents each independently selected from fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, oxo, $-NH_2$, =N-OH or cyclopropyl;

(iv) a 5- to 6-membered heteroaryl selected from thiophen-2-yl, thiophen-3-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, 1H-pyrazol-4-yl, thiazol-2-yl, or isothiazol-4-yl, where said 5- to 6-membered heteroaryl is optionally substituted with 1 to 3 substituents each independently selected from fluoro, chloro, methyl, ethyl, isopropyl, hydroxy, difluoromethyl, trifluoromethyl, methoxy, $-NH_2$, $-NHC(O)CH_3$, $-C(O)NHCH_3$, or pyrrolidin-1-yl; or

(v) a fused heteroaryl selected from benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, quinolin-2-yl, quinolin-3-yl, benzooxazol-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-thieno[2,3-c]pyridin-2-yl, imidazo[1,2-a]pyridin-3-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyridin-7-yl, 3H-imidazo[4,5-b]pyridin-6-yl, thieno[3,2-c]pyridin-2-yl, thieno[3,2-c]pyridin-3-yl, or 1H-indol-3-yl, where said fused heteroaryl is optionally substituted with 1 to 4 substituents each independently selected from fluoro, chloro, cyano, methyl, or methoxy;

or a pharmaceutically acceptable salt thereof.

14. The compound of Claim 6, 7, 8, 9, 10, 11, 12 or 13 wherein R^{53} is

(i) a phenyl optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethyl, or cyano;

(ii) a biphenyl;

(iii) a fused phenyl selected from naphthalen-2-yl, quinolin-6-yl, 3,4-dihydro-2-oxo-quinolin-6-yl, benzo[b]thiophen-5-yl, benzo[d]isoxazol-5-yl, 1H-indazol-6-yl, 1H-indazol-5-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or benzo[1,3]dioxol-5-yl where said fused phenyl is optionally substituted with 1 to 2 substituents each independently selected from chloro, fluoro, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyano, or amino;

(iv) a 5- to 6-membered heteroaryl selected from isothiazol-4-yl, thiophen-2-yl, thiophen-3-yl, or pyridin-4-yl, where said isothiazol-4-yl, said thiophen-2-yl, said

thiophen-3-yl, and said pyridin-4-yl are optionally substituted with fluoro, chloro, methyl, trifluoromethyl, difluoromethyl, or methoxy; or

(v) a fused heteroaryl selected from thieno[3,2-c]pyridin-2-yl, thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, imidazo[1,2-a]pyridin-7-yl, or benzo[b]thiophen-2-yl, where said fused heteroaryl is optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, or amino;

or a pharmaceutically acceptable salt thereof.

15. The compound of Claim 6, 7, 8, 9, 10, 11, 12, 13 or 14 wherein R^{53} is phenyl, 4-chloro-3-fluoro-phenyl, m-tolyl, 3-methoxy-phenyl, 3-chloro-4-fluoro-phenyl, 4-fluoro-3-methyl-phenyl, 3-trifluoromethyl-phenyl, 3-chloro-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3-difluoromethyl-4-fluoro-phenyl, 3-cyano-4-fluorophenyl, 3-cyanophenyl, 3-chloro-4-cyanophenyl, 3,4-difluoro-phenyl, 4-trifluoromethyl-phenyl;

or a pharmaceutically acceptable salt thereof.

16. The compound of 6, 7, 8, 9, 10, 11, 12, 13 or 14 wherein R^{53} is naphthalen-2-yl, benzo[b]thiophen-5-yl, 3-methyl-benzo[d]isoxazol-5-yl, 1H-indazol-5-yl, 1-methyl-1H-indazol-5-yl, 3-amino-1H-indazol-5-yl, 1H-indazol-6-yl, 3-amino-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl, 3-trifluoromethyl-1H-indazol-6-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, 3-methyl-benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or 2,2-difluoro-benzo[1,3]dioxol-5-yl;

or a pharmaceutically acceptable salt thereof.

17. The compound of Claim 16 wherein R^{53} is benzothiazol-6-yl, 3-methyl-benzofuran-5-yl, 1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl, or 3-trifluoromethyl-1H-indazol-6-yl;

or a pharmaceutically acceptable salt thereof.

18. The compound of 6, 7, 8, 9, 10, 11, 12, 13 or 14 wherein R^{53} is 5-methyl-thiophen-2-yl, 5-chloro-thiophen-2-yl, 5-trifluoromethyl-thiophen-2-yl, 5-difluoromethyl-thiophen-3-yl, 5-methyl-thiophen-3-yl, 2-methyl-pyridin-4-yl, 2-trifluoromethyl-pyridin-4-yl, 2-chloro-pyridin-4-yl, or 2-methoxy-pyridin-4-yl;

or a pharmaceutically acceptable salt thereof.

19. The compound of 6, 7, 8, 9, 10, 11, 12, 13 or 14 wherein R^{53} is 4-chloro-thieno[3,2-c]pyridin-2-yl, 4-chloro-thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, 3-chloro-imidazo[1,2-a]pyridin-7-yl, benzo[b]thiophen-2-yl, or 4-methylthieno[3,2-c]pyridin-2-yl;

or a pharmaceutically acceptable salt thereof.

20. A compound selected from the group consisting of

1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-(4-Chloro-thieno[3,2-c]pyridin-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one ;

1-(1H-Indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-(3-Difluoromethyl-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one;

1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-3-yl)-1,3-dihydro-imidazol-2-one;

1-(3-Methyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-Benzo[b]thiophen-5-yl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one; and

1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one;

or a pharmaceutically acceptable salt thereof.

21. A compound selected from the group consisting of

1-Naphthalen-2-yl-3-pyridin-3-yl-imidazolidin-2-one;

1-Benzo[b]thiophen-5-yl-3-pyridin-3-yl-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-naphthalen-2-yl-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-2-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzo[b]thiophen-2-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzo[b]thiophen-5-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(1H-Indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Methyl-benzofuran-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(5-Chloro-thiophen-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3,4-Difluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Chloro-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2,3-Dihydro-benzofuran-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Chloro-3-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-m-tolyl-imidazolidin-2-one;
1-(3-Methoxy-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Fluoro-3-methyl-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-phenyl-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(3-trifluoromethyl-phenyl)-imidazolidin-2-one;
1-(2-Methoxy-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(5-Difluoromethyl-thiophen-3-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Chloro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Fluoro-3-trifluoromethyl-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Difluoromethyl-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-3-yl)-imidazolidin-2-one;
1-(4-Chloro-thieno[3,2-c]pyridin-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Chloro-thieno[3,2-c]pyridin-3-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(2-methyl-pyridin-4-yl)-imidazolidin-2-one;
1-(3-Methyl-benzo[d]isoxazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Methyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
2-Fluoro-5-[3-(4-methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile;
3-[3-(4-Methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile;
2-Chloro-4-[3-(4-methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile;
1-(1-Methyl-1H-indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Amino-1H-indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-thieno[3,2-c]pyridin-2-yl-imidazolidin-2-one;
1-(1H-Indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Amino-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methoxy-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-difluoromethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-hydroxymethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-trifluoromethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Indan-5-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(1H-Benzotriazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Chloro-imidazo[1,2-a]pyridin-7-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(2-trifluoromethyl-pyridin-4-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-dimethoxymethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(5-chloro-4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methylpyridin-3-yl)-3-(5-(trifluoromethyl)thiophen-2-yl)imidazolidin-2-one;
1-(4-Methylpyridin-3-yl)-3-(4-methylthieno[3,2-c]pyridin-2-yl)imidazolidin-2-one;

1-(Benzo[d]thiazol-6-yl)-3-(4-(1-hydroxyethyl)pyridin-3-yl)imidazolidin-2-one;
1-(Benzo[d]thiazol-6-yl)-3-(4-ethylpyridin-3-yl)imidazolidin-2-one;
1-(4-Methylpyridin-3-yl)-3-(3-(trifluoromethyl)-1H-indazol-6-yl)imidazolidin-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4-ethyl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one;
1-Benzothiazol-6-yl-4-ethyl-3-pyridin-3-yl-1,3-dihydro-imidazol-2-one;
1-Benzothiazol-6-yl-3-pyridin-3-yl-4-trifluoromethyl-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-benzoimidazol-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
3-Benzothiazol-6-yl-1-pyridin-3-yl-4-trifluoromethyl-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-4-trifluoromethyl-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,5-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-pyrrolidin-1-ylmethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-morpholin-4-ylmethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-cyclopropylaminomethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(6-fluoro-4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-[4-(2-morpholin-4-yl-ethoxy)-pyridin-3-yl]-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-[4-(1-methyl-pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-{4-[(5-methyl-1H-pyrazol-3-ylamino)-methyl]-pyridin-3-yl}-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(3H-imidazo[4,5-b]pyridin-6-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-[4-(1-methyl-piperidin-4-ylmethoxy)-pyridin-3-yl]-imidazolidin-2-one;
3-(3-Benzothiazol-6-yl-2-oxo-imidazolidin-1-yl)-isonicotinamide;

1-Benzothiazol-6-yl-3-imidazo[1,2-a]pyrazin-5-yl-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-imidazolidin-2-one;
3-Benzothiazol-6-yl-3'-methyl-4,5-dihydro-3H,3'H-[1,4']biimidazolyl-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-5-trifluoromethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Isothiazol-4-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-pyridin-2-yl-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(5-trifluoromethyl-thiophen-2-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-[4-(1-hydroxy-1-methyl-ethyl)-pyridin-3-yl]-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(4-methyl-thieno[3,2-c]pyridin-2-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-[4-(1-hydroxy-ethyl)-pyridin-3-yl]-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-ethyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(3-trifluoromethyl-1H-indazol-6-yl)-imidazolidin-2-one;
1-(3-Cyclopropyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-quinolin-7-yl-imidazolidin-2-one;
3-Benzothiazol-6-yl-4,4-dimethyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,4-dimethyl-3-pyridin-3-yl-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,4-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one; and
3-Benzothiazol-6-yl-4-methyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,5-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-pyrrolidin-1-ylmethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-morpholin-4-ylmethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-cyclopropylaminomethyl-pyridin-3-yl)-imidazolidin-2-one;

1-Benzothiazol-6-yl-3-{4-[(5-methyl-1H-pyrazol-3-ylamino)-methyl]-pyridin-3-yl}-imidazolidin-2-one;

1-Benzothiazol-6-yl-4,4-dimethyl-3-pyridin-3-yl-imidazolidin-2-one; and

3-Benzothiazol-6-yl-4-methyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a compound of Claims 1 through 21 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

23. The pharmaceutical composition of Claim 22 further comprising at least one additional pharmaceutical agent wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound.

24. A method for treating a disease, disorder, or syndrome mediated by Cyp17 inhibition comprising the step of administering a compound of claims 1 to 21 to a subject in need of such treatment.

25. A method for treating a disease, disorder, or syndrome mediated by Cyp17 inhibition comprising the step of administering a pharmaceutical composition of Claim 22 to a subject in need of such treatment.

26. A method for treating a disease, disorder or syndrome mediated by Cyp17 inhibition comprising the step of administering

(i) a first composition comprising a compound of Claim 1 through 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient; and

(ii) a second composition comprising at least one additional pharmaceutical agent and a pharmaceutically acceptable carrier or excipient;

wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound.

27. The method of Claim 26 wherein said first composition and said second composition are administered simultaneously.

28. The method of Claim 26 wherein said first composition and said second composition are administered sequentially in any order.

29. The use of a compound according to Claims 1 through 21 for the treatment of a disease, disorder, or syndrome mediated by Cyp17 inhibition.

Claims

1. A compound of Formula (Ia) or (Ib)



(Ia)



(Ib)

wherein:

n is 1, 2, or 3;
R^{53} is

(i) a phenyl optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethyl, or cyano;
(ii) a biphenyl;
(iii) a fused phenyl selected from naphthalen-2-yl, quinolin-6-yl, 3,4-dihydro-2-oxo-quinolin-6-yl, benzo[b]thiophen-5-yl, benzo[d]isoxazol-5-yl, 1H-indazol-6-yl, 1H-indazol-5-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or benzo[1,3]dioxol-5-yl where said fused phenyl is optionally substituted with 1 to 2 substituents each independently selected from chloro, fluoro, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyano, or amino;
(iv) a 5- to 6-membered heteroaryl selected from isothiazol-4-yl, thiophen-2-yl, thiophen-3-yl, or pyridin-4-yl, where said isothiazol-4-yl, said thiophen-2-yl, said thiophen-3-yl, and said pyridin-4-yl are optionally substituted with fluoro, chloro, methyl, trifluoromethyl, difluoromethyl, or methoxy; or
(v) a fused heteroaryl selected from thieno[3,2-c]pyridin-2-yl, thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, imidazo[1,2-a]pyridin-7-yl, or benzo[b]thiophen-2-yl, where said fused heteroaryl is optionally substituted with 1 to 2 substituents each independently selected from fluoro, chloro, methyl, difluoromethyl, trifluoromethyl, cyclopropyl, or amino;

R^{54} is $(C_1\text{-}C_4)$alkyl, halo-substituted $(C_1\text{-}C_4)$alkyl, or $-CH_2OH$;
p is 0, 1, 2, or 3;
q is 0, 1 or 2;
R^{50}, R^{51} and R^{52} are each independently H, halo, -OH, -CN, $(C_1\text{-}C_4)$alkyl, halo-substituted$(C_1\text{-}C_4)$alkyl, hydroxy-substituted $(C_1\text{-}C_4)$alkyl, $-(CH_2)_r\text{-}O(C_1\text{-}C_4)$alkyl, $-(CH_2)_r\text{-}CH(O(C_1\text{-}C_4)akyl)_2$, $-NH_2$, $-NH(C_1\text{-}C_4)$alkyl, $-N((C_1\text{-}C_4)alkyl)_2$, $-NHC(O)\text{-}(C_1\text{-}C_4)$alkyl, $-C(O)NH_2$, $-C(O)\text{-}NH(C_1\text{-}C_4)$alkyl, $-C(O)\text{-}N((C_1\text{-}C_4)alkyl)_2$, or $-C(O)\text{-}O(C_1\text{-}C_4)$alkyl;
r is 0, 1 or 2;
with the proviso that when R^{50}, R^{51}, and R^{52} are H and R^{53} is phenyl, R^{53} is not unsubstituted or substituted with halogen or CF_3;
or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1 wherein said compound is a compound of Formula (Ia); or a pharmaceutically acceptable salt thereof.

3. The compound of Claim 2 where q is 0; or a pharmaceutically acceptable salt thereof.

4. The compound of Claim 1 wherein said compound is a compound of Formula (Ib); or a pharmaceutically acceptable salt thereof.

5. The compound of Claim 4 wherein R^{54} is $-CH_3$ or CF_3; or a pharmaceutically acceptable salt thereof.

6. The compound of Claim 4 or 5 wherein n is 1; or a pharmaceutically acceptable salt thereof.

7. The compound of Claim 1, 2, 3, 4, 5 or 6 wherein R^{50} is H or methyl; R^{51} is H, halo, methyl, trifluoromethyl, methoxy, or $-C(O)OCH_3$; and R^{52} is halo, -CN, methyl, ethyl, methoxy, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropan-2-yl, difluoromethyl, trifluoromethyl, dimethoxymethyl, $-NH_2$, or $NHC(O)CH_3$; or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 1, 2, 3, 4, 5, 6 or 7, wherein R^{53} is phenyl, 4-chloro-3-fluoro-phenyl, m-tolyl, 3-methoxy-phenyl, 3-chloro-4-fluoro-phenyl, 4-fluoro-3-methyl-phenyl, 3-trifluoromethyl-phenyl, 3-chloro-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3-difluoromethyl-4-fluoro-phenyl, 3-cyano-4-fluorophenyl, 3-cyanophenyl, 3-chloro-4-cyano-phenyl, 3,4-difluoro-phenyl, 4-trifluoromethyl-phenyl;
or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, 2, 3, 4, 5, 6 or 7, wherein R^{53} is naphthalen-2-yl, benzo[b]thiophen-5-yl, 3-methyl-benzo[d]isoxazol-5-yl, 1H-indazol-5-yl, 1-methyl-1H-indazol-5-yl, 3-amino-1H-indazol-5-yl, 1H-indazol-6-yl, 3-amino-1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl, 3-trifluoromethyl-1H-indazol-6-yl, benzothiazol-6-yl, 1,2-dihydro-3-oxo-indazol-6-yl, indan-5-yl, 1H-benzotriazol-5-yl, 3-methyl-benzofuran-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, or 2,2-difluoro-benzo[1,3]dioxol-5-yl;
or a pharmaceutically acceptable salt thereof.

10. The compound of Claim 9 wherein R^{53} is benzothiazol-6-yl, 3-methyl-benzofuran-5-yl, 1H-indazol-6-yl, 3-methyl-1H-indazol-6-yl, or 3-trifluoromethyl-1H-indazol-6-yl;
or a pharmaceutically acceptable salt thereof.

11. The compound of claims 1, 2, 3, 4, 5, 6 or 7, wherein R^{53} is 5-methyl-thiophen-2-yl, 5-chloro-thiophen-2-yl, 5-trifluoromethyl-thiophen-2-yl, 5-difluoromethyl-thiophen-3-yl, 5-methyl-thiophen-3-yl, 2-methyl-pyridin-4-yl, 2-trifluoromethyl-pyridin-4-yl, 2-chloro-pyridin-4-yl, or 2-methoxy-pyridin-4-yl;
or a pharmaceutically acceptable salt thereof.

12. The compound of claims 1, 2, 3, 4, 5, 6 or 7, wherein R^{53} is 4-chloro-thieno[3,2-c]pyridin-2-yl, 4-chloro-thieno[3,2-c]pyridin-3-yl, thieno[3,2-c]pyridin-2-yl, 3-chloro-imidazo[1,2-a]pyridin-7-yl, benzo[b]thiophen-2-yl, or 4-methylthieno[3,2-c]pyridin-2-yl;
or a pharmaceutically acceptable salt thereof.

13. A compound of claim 1, selected from the group consisting of
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Chloro-thieno[3,2-c]pyridin-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(1H-Indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Difluoromethyl-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-3-yl)-1,3-dihydro-imidazol-2-one;
1-(3-Methyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzo[b]thiophen-5-yl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one; and
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one;
or a pharmaceutically acceptable salt thereof.

14. A compound of claim 1 selected from the group consisting of
1-Naphthalen-2-yl-3-pyridin-3-yl-imidazolidin-2-one;
1-Benzo[b]thiophen-5-yl-3-pyridin-3-yl-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-naphthalen-2-yl-imidazolidin-2-one;

1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-2-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzo[b]thiophen-5-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(1H-Indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Methyl-benzofuran-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(5-Chloro-thiophen-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3,4-Difluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Chloro-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;

1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2,3-Dihydro-benzofuran-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Chloro-3-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-m-tolyl-imidazolidin-2-one;
1-(3-Methoxy-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Fluoro-3-methyl-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-phenyl-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(3-trifluoromethyl-phenyl)-imidazolidin-2-one;
1-(2-Methoxy-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(5-Difluoromethyl-thiophen-3-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Chloro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Fluoro-3-trifluoromethyl-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Difluoromethyl-4-fluoro-phenyl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(5-methyl-thiophen-3-yl)-imidazolidin-2-one;
1-(4-Chloro-thieno[3,2-c]pyridin-2-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Chloro-thieno[3,2-c]pyridin-3-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(2-methyl-pyridin-4-yl)-imidazolidin-2-one;
1-(3-Methyl-benzo[d]isoxazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Methyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
2-Fluoro-5-[3-(4-methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile;
3-[3-(4-Methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile;
2-Chloro-4-[3-(4-methyl-pyridin-3-yl)-2-oxo-imidazolidin-1-yl]-benzonitrile;
1-(1-Methyl-1H-indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Amino-1H-indazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-thieno[3,2-c]pyridin-2-yl-imidazolidin-2-one;
1-(1H-Indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Amino-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methoxy-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-difluoromethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-hydroxymethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-trifluoromethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Indan-5-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(1H-Benzotriazol-5-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(3-Chloro-imidazo[1,2-a]pyridin-7-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(2-trifluoromethyl-pyridin-4-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-dimethoxymethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(5-chloro-4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methylpyridin-3-yl)-3-(5-(trifluoromethyl)thiophen-2-yl)imidazolidin-2-one;
1-(4-Methylpyridin-3-yl)-3-(4-methylthieno[3,2-c]pyridin-2-yl)imidazolidin-2-one;
1-(Benzo[d]thiazol-6-yl)-3-(4-(1-hydroxyethyl)pyridin-3-yl)imidazolidin-2-one;
1-(Benzo[d]thiazol-6-yl)-3-(4-ethylpyridin-3-yl)imidazolidin-2-one;
1-(4-Methylpyridin-3-yl)-3-(3-(trifluoromethyl)-1H-indazol-6-yl)imidazolidin-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4-ethyl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-imidazol-2-one;
1-Benzothiazol-6-yl-4-ethyl-3-pyridin-3-yl-1,3-dihydro-imidazol-2-one;
1-Benzothiazol-6-yl-3-pyridin-3-yl-4-trifluoromethyl-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-1,3-dihydro-benzoimidazol-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
3-Benzothiazol-6-yl-1-pyridin-3-yl-4-trifluoromethyl-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-methyl-pyridin-3-yl)-4-trifluoromethyl-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,5-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(6-fluoro-4-methyl-pyridin-3-yl)-imidazolidin-2-one;
3-(3-Benzothiazol-6-yl-2-oxo-imidazolidin-1-yl)-isonicotinamide;
1-Benzothiazol-6-yl-3-(4-methyl-5-trifluoromethyl-pyridin-3-yl)-imidazolidin-2-one;
1-Isothiazol-4-yl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(5-trifluoromethyl-thiophen-2-yl)-imidazolidin-2-one;

1-Benzothiazol-6-yl-3-[4-(1-hydroxy-1-methyl-ethyl)-pyridin-3-yl]-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(4-methyl-thieno[3,2-c]pyridin-2-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-[4-(1-hydroxy-ethyl)-pyridin-3-yl]-imidazolidin-2-one;
1-Benzothiazol-6-yl-3-(4-ethyl-pyridin-3-yl)-imidazolidin-2-one;
1-(4-Methyl-pyridin-3-yl)-3-(3-trifluoromethyl-1H-indazol-6-yl)-imidazolidin-2-one;
1-(3-Cyclopropyl-1H-indazol-6-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
3-Benzothiazol-6-yl-4,4-dimethyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,4-dimethyl-3-pyridin-3-yl-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,4-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
3-Benzothiazol-6-yl-4-methyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4-methyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,5-dimethyl-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
1-Benzothiazol-6-yl-4,4-dimethyl-3-pyridin-3-yl-imidazolidin-2-one; and
3-Benzothiazol-6-yl-4-methyl-1-(4-methyl-pyridin-3-yl)-imidazolidin-2-one;
or a pharmaceutically acceptable salt thereof.

15. A compound of claim 1 which is 1-(2-chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one having the structure:



or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

17. The pharmaceutical composition of Claim 16 further comprising at least one additional pharmaceutical agent wherein said at least one additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound.

18. The use of a compound according to any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease, disorder, or syndrome mediated by Cyp17 inhibition.

19. A compound according to any one of claims 1 to 15 for use in medicine.

20. A compound according to claim 19 for use in the treatment of a disease, disorder, or syndrome mediated by Cyp17 inhibition.

21. A compound according to claim 20, or use according to claim 18, wherein the disease, disorder, or syndrome mediated by Cyp17 inhibition is inflammation or cancer.

22. A compound according to claim 21, or use according to claim 21, wherein the cancer is prostate cancer.

23. The pharmaceutical composition of claim 17 for use in the treatment of cancer, wherein the additional pharmaceutical agent which is an anticancer agent, chemotherapy agent, or antiproliferative compound, is administered simultaneously with the compound of any one of claims 1-15, or the additional pharmaceutical agent which is an anticancer agent, chemotherapy agent, or antiproliferative compound and the compound of any one of claims 1-15 are administered sequentially in any order.